Meet the Team

Edwin Moses was Chief Executive Officer of Ablynx NV until its agreed takeover by Sanofi for $4.8 billion in 2018. He was CEO of Ablynx for more than 12 years and built it from a small R&D-focused organisation into a 500-person commercial-ready business. The company developed a broad biologics pipeline including a wholly-owned product for a rare hematologic indication, which was approved for use in Europe in 2018 and the USA in 2019. While at Ablynx, Edwin led its Euronext Brussels listing, multiple successful private and public financings and its US NASDAQ listing in 2017 which raised $230M. He was also responsible for delivering a series of multi-billion-pound collaborations with major pharmaceutical companies.

Edwin has more than 25 years of Board level experience, both as CEO and Chairman, at more than 10 European life science companies. During his career to date, he has raised more than €500M in equity and debt financing. Edwin is currently also Chair of Achilles Therapeutics plc and Avantium NV.

James is the CEO of LabGenius, a next-generation antibody discovery company. 

LabGenius has pioneered the development of an ML-driven protein engineering platform that’s capable of designing, conducting and critically learning from its own experiments. 

As CEO, James has raised >$70M in financing from top-tier VCs (e.g. M Ventures, Octopus Ventures, Lux Capital, Obvious Ventures, Atomico and Kindred) and struck R&D deals with top pharma companies like Sanofi. 

Prior to founding LabGenius, James completed a PhD at Imperial College where he developed novel methods for re-engineering protein nanocages for targeted drug delivery.

Irina Haivas is a Partner at Atomico. She is passionate about machine intelligence-enabled businesses, next generation biology, robotics and automation, and other frontier technologies. She also focuses on companies in healthcare.

Before joining Atomico, Irina was a growth and PE investor at healthcare-focused fund GHO Capital, and a strategy consultant at Bain & Co. where she worked with over 30 companies across Europe and the US.

Irina trained as a doctor, and was a surgical fellow at Harvard Medical School before completing an MSc (Dist) in International Health Policy at the London School of Economics.

Ollie is a successful entrepreneur with core expertise in the bioprocessing field, and interest more broadly in life sciences & manufacturing technologies.

Completing his Engineering Doctorate at UCL 2012, he moved into the entrepreneurial world founding Puridify, a biotech tools company, which he led as CEO through VC funding to a strong exit by GE Healthcare in 2017, interacting with biotherapeutic manufacturers globally throughout this journey.

Having spent 5 years leading an SME followed by 5 years in a large corporate he understands the needs of both and can provide key insights to spin-outs & start-ups from inception to exit.

He has served two elected terms as board member of BioIndustry Association (BIA), an influential trade association promoting the ecosystem for innovative life sciences in the UK.

Oliver is an Investor Director of LabGenius representing Octopus Ventures where he specialises in early-stage Biotech investments.

Oliver has a background in Biomedical Science and Biochemistry, from there he transitioned to commercialising scientific ideas within Biotech and Pharmaceutical industry in Business/Corporate Development and Entrepreneurship. His experiences range through, multi-specific biologics for drug discovery, gene editing tools and therapies, diagnosing diseases using breath and real-time prediction of episodes in Bipolar patients.

He began in Venture Capital working for Jonathan Milner (Founding CEO of Abcam); helping run his family office and investing broadly across Biotech at all stages from pre-seed to IPOs.

Christian Uhrich joined M Ventures in August 2019 as Head of Strategy and is currently an Investment Director in the Biotechnology team. He represents M Ventures on several portfolio company boards across Therapeutics and Life Science Tools and Technology companies.

Previously, he worked at Merck as a Senior Consultant in its Inhouse Consulting practice where he focused on impactful strategy related projects across all three business sectors of Merck (Healthcare, Life Science, Electronics).

Before joining Merck, Christian spent over ten years in the external consulting space, previously working for Accenture in its Strategy practice where he successfully consulted key Pharma and Biotech industry players on strategic challenges and management decisions in the areas of R&D, marketing & sales, organisational development and transformation, and post-merger integration & carve-outs.

Christian holds an MBA from Mannheim Business School, Germany and a Diploma in Computer Science and Business Administration (Business Informatics) from Cooperative State University Karlsruhe, Germany. Christian is based in Germany.

Leila is a founding partner at Kindred Capital and acts as Board Observer at LabGenius.

She is both an investor and an entrepreneur, with over a decade of operating experience in technology businesses across three continents.

Leila holds an MBA from Harvard Business School, as well as a BS in Mathematics and Philosophy from Yale University. Leila was also part of the founding team of GenapSys, a DNA sequencing company that raised over $50 million.